Targeted Anticoagulants Move From Lab to Patient Trials

Host: Bruce Japsen Guest: Ted Love, MD Anticoagulants like heparin have been around for decades, but the drugs have drawbacks for many patients. Dr. Ted Love, Chief Executive of biotech company Nuvelo, tells host Bruce Japsen about targeted anticoagulant therapies that are being developed to be safer and more effective than the old standby heparin therapy and other blood treatments.